Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,847
datasets available to search
ShareScore release 0.9.0
Dataset results
1,847 results for “Psoriasis”
FTO alleviates psoriasis-like dermatitis through the regulation of FN1
GEO Series GSE253791. Homo sapiens. 9 samples. Type: Expression profiling by high throughput sequencing.
Monocytes as endogenous immunologic biosensors: identification of inflammatory, adhesion, and mTOR-related signatures in psoriasis
GEO Series GSE161906. Homo sapiens. 24 samples. Type: Expression profiling by high throughput sequencing.
Effect of Itolizumab on gene expression profiles of patients enrolled in phase 2 psoriasis clinical trial study (Study number: T1hAb‐CT1‐001‐07).
GEO Series GSE72246. Homo sapiens. 48 samples. Type: Expression profiling by array.
Molecular analysis in imiquimod (IMQ)-induced psoriasis model
GEO Series GSE152637. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Development of gene expression signatures for psoriasis
GEO Series GSE181318. Homo sapiens. 6 samples. Type: Expression profiling by array; Non-coding RNA profiling by array.
Transcriptomic analysis of low-density neutrophils (LDNs) in acute generalized pustular psoriasis (GPP)
GEO Series GSE200836. Homo sapiens. 11 samples. Type: Expression profiling by high throughput sequencing.
Single-cell transcriptomic analysis identifies infiltrating plasmacytoid dendritic cells in psoriasis epidermis
GEO Series GSE254707. Homo sapiens. 4988 samples. Type: Expression profiling by high throughput sequencing.
Transcriptomes of MPO-deficient patients with generalized pustular psoriasis reveals expansion of CD4+ cytotoxic T cells and an involvement of the complement system
GEO Series GSE181994. Homo sapiens. 7 samples. Type: Expression profiling by high throughput sequencing.
DNA Methylation Profile in Psoriasis Vulgaris and Generalized Pustular Psoriasis Patients
GEO Series GSE304903. Homo sapiens. 4 samples. Type: Methylation profiling by high throughput sequencing.
Low-input mRNA Sequencing Analysis of Epidermal Langerhans cells (LC) from Murine Imiquimod (IMQ)-Induced Psoriasis-Like Dermatitis
GEO Series GSE162274. Mus musculus. 8 samples. Type: Expression profiling by high throughput sequencing.
Inflammasome Signaling and Impaired Vascular Health in Psoriasis
GEO Series GSE147339. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing.
Neuronal Ash1L Gates Skin Psoriasis Via Activity-dependent Release of miR-let-7b
GEO Series GSE215333. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Skin expression data from psoriasis patients treated with IL-17A inhibitor
GEO Series GSE212476. Homo sapiens. 40 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Real-life Effectiveness and Safety of Risankizumab in Moderateto- severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study"
<p>This record contains data related to article "Real-life Effectiveness and Safety of Risankizumab in Moderateto- severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study"</p> <p>Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in monotherapy up to week 40 in a “real-life” setting. At week 40, 98.7%, 85.7% and 62.3% of patients achieved a Psoriasis Area and Severity Index (PASI) reduction ≥ 75% (PASI 75), PASI 90 and PASI 100, respectively. Patients who had not responded to 2 or more previous biologic treatments were significantly less likely to achieve PASI 75/90 at week 16 and PASI 90/100 at week 40 compared<br> with those who had been previously treated with<br> only 1 biologic, and compared with those treated with risankizumab as a first-line biologic. Increasing body mass index decreased the chances of reaching PASI 90 at week 40. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment. These data suggest that the efficacy of risankizumab for plaque psoriasis in “real-life” clinical practice could differ from pivotal clinical trials data.</p>
Dataset related to article "Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: longterm safety in a single- center real-life population"
<p>This record contains data related to article "Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: longterm safety in a single- center real-life population"</p> <p>ABSTRACT</p> <p>Introduction: This is an Italian single-center retrospective study evaluating safety and efficacy of biologic agents in psoriatic patients with a previous diagnosis of malignant cancer.</p> <p>Aim: Management of moderate and severe psoriasis patients with a past medical history of malignancies could be difficult because biologic agents are historically associated with a presumptive increased risk of neoplastic reactivation or of a new incoming cancer. The aim of this study is to assess the safety of biologics in patients with a previous cancer diagnosis.</p> <p>Material and methods: The study analyzed 16 moderate to severe psoriasis patients with a diagnosis of malignant cancer in the previous 10 years treated with biologic agents for up to at least 96 weeks. In five of these patients, cancer was diagnosed in the previous 5 years.</p> <p>Results: We observed a rapid decrease in PASI (psoriasis area severity index) reaching a 90% improvement in 100% of patients. Oncologic follow up did not show any worsening or reactivation of cancer during the entire observation period. No new malignancies were observed in the analyzed sample.</p> <p>Conclusions: Biologic agents in our experience have demonstrated to be safe and effective in psoriatic patients with a past medical history of malignant cancer.</p>
Dataset related to article "Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study "
<p>This record contains raw data related to article “Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study"</p> <p>Abstract</p> <p><strong>Introduction: </strong> There are no strong data regarding the treatment with biologics (especially for the most recent anti-IL-17 and anti-IL-23 drugs) of patients with psoriasis and concomitant viral hepatitis. We assessed the safety of biologic drugs in patients with psoriasis who are seropositive for hepatitis B or C and did not receive antiviral prophylaxis.</p> <p><strong>Methods: </strong> We conducted a retrospective single-center study. The efficacy of biologic treatments was evaluated by assessing the Psoriasis Area and Severity Index (PASI) score during all visits, for a minimum follow-up of 52 weeks. All patients were evaluated by a hepatologist before starting the treatment. They were monitored for reactivation of viral hepatitis.</p> <p><strong>Results: </strong> Twenty patients had positive markers of hepatitis B virus (HBV) or hepatitis C virus (HCV). Seventeen patients had positive markers of HBV infection, and four patients had antibodies for HCV (one patient had serologic evidence of both infections). Anti-IL-23 biologics were the most used in our population, with risankizumab being the most prescribed drug. No patient had evidence of viral reactivation during our study. Study limitations include its retrospective nature and our inclusion of patients with different serological status receiving different biologic drugs.</p> <p><strong>Conclusion: </strong> Biologic therapies (including anti-IL-23 drugs) appear to be safe in patients seropositive for HCV or HBV core antibody who did not receive antiviral prophylaxis.</p>
Dataset related to article "Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study"
<p>This record contains raw data related to article “Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study"</p> <p>Abstract</p> <p><strong>Introduction: </strong> Risankizumab is a humanized monoclonal antibody that selectively targets interleukin-23. It is approved for treatment of moderate-to-severe plaque psoriasis. We conducted a 52-week monocentric retrospective study to evaluate the effectiveness and safety of risankizumab in a real-life setting.</p> <p><strong>Methods: </strong> Our study included 131 adults with moderate-to-severe plaque psoriasis all treated with risankizumab for at least 52 weeks. Patient characteristics and PASI (Psoriasis Area and Severity Index) at each visit were recorded. The percentages of patients achieving 75%/90%/100% (PASI 75/90/100) improvement in PASI with respect to baseline were registered.</p> <p><strong>Results: </strong> At week 52, 93.9%, 78.6%, and 61.1% of patients achieved PASI 75/90/100, respectively. An absolute PASI ≤ 2 was reached by 90.8% at week 52. The higher body mass index and the presence of cardio-metabolic comorbidities did not interfere with the odds of reaching PASI 75/90/100 at each time-point. At week 52, comparable percentages of patients achieved PASI 100, regardless of the involvement of difficult-to-treat-areas. No significant safety findings were recorded and none of the patients had to interrupt the treatment because of adverse events.</p> <p><strong>Conclusions: </strong> Our findings confirmed that risankizumab is a safe and effective therapeutic option for the treatment of a wide "real-life" cohort of patients with psoriasis.</p>
Dataset related to article "Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study "
<p>This record contains raw data related to article “Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study"</p> <p>Abstract</p> <p>Scalp is a frequent localization of psoriasis that has a massive impact on patient's quality of life. Managing this psoriasis' manifestation is often challenging, thus biologic drugs are widely used as a treatment option in refractory scalp psoriasis. The aim of our study is to retrospectively compare the efficacy of anti-interleukin (IL) 23 drugs (guselkumab, tildrakizumab, risankizumab) and anti-IL17 or anti-IL17RA biologics (secukinumab, ixekizumab, and brodalumab) in real-life patients affected by scalp psoriasis. One hundred twenty-seven patients with a clinical diagnosis of scalp psoriasis and a baseline scalp Physician Global Assessment ≥3 were enrolled; 65 patients were treated with anti-IL23 and anti-IL62 with anti-IL17 or anti-IL17RA. Statistical analysis trough χ<sup>2</sup> test was performed in order to evaluate the percentage of response among the two groups of patients. Responders' percentage of patients under anti-IL23 was 41.5%, 75.4%, 88.1%, 87.5%, 93.7%, and 100% at Week 4, 16, 48, 96, and 144, respectively. In the group on anti-IL17 was 62.9%, 90.3%, 91.2%, 97.3%, 96.9%, and 95.2% at Week 4, 16, 48, 96, and 144, respectively. Both anti-IL17 and anti-IL23 appeared to be effective on scalp psoriasis; in particular patients treated with anti-IL17 drugs reached a faster significant reduction of the lesions; on the other hand, anti-IL23 monoclonal antibodies were slightly superior in maintaining the clinical improvement through the follow-up.</p>
Big data-driven target identification by machine learning: DRD2 as a therapeutic target for psoriasis.
GEO Series GSE276511. Mus musculus. 10 samples. Type: Expression profiling by high throughput sequencing.
Expression data from Imiquimod-induced psoriasis mouse model
GEO Series GSE104603. Mus musculus. 12 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.